CCT129202 is primarily utilized in biomedical research, particularly in the study of cancer and cellular signaling pathways. It functions as a potent and selective inhibitor of protein kinase B (PKB/AKT), a key regulator of cell survival, growth, and metabolism. By inhibiting AKT, CCT129202 helps researchers investigate the role of this pathway in tumor development and progression. It is often employed in laboratory studies to explore potential therapeutic strategies for cancers that exhibit dysregulated AKT signaling, such as breast, prostate, and ovarian cancers. Additionally, it aids in understanding drug resistance mechanisms and identifying combination therapies to enhance the efficacy of existing cancer treatments. Its application extends to preclinical models, where it is used to evaluate the impact of AKT inhibition on tumor growth and metastasis.